畸胎癌衍生生长因子1在胰腺导管腺癌中的表达与临床意义

Expression of Cripto-1 in pancreatic ductal adenocarcinoma and its clinical significance

目的:探讨畸胎癌衍生生长因子1(Cripto-1)在胰腺导管腺癌组织中的表达与临床意义。方法:采用免疫组化法检测62例胰腺导管腺癌组织中Cripto-1的表达,结合临床病理特征进行分析。结果:Cripto-1在胰腺导管腺癌组织中的阳性率为67.7%。高、中、低分化导管腺癌病人中的Cripto-1阳性率分别为27.3%、67.6%、94.1%,差异有统计学意义(P<0.05)。无血管侵犯和有血管侵犯病人中的Cripto-1阳性率分别为58.7%和93.8%,差异有统计学意义(P<0.05)。无淋巴结转移和有淋巴结转移的病人中的Cripto-1阳性率分别为53.8%和91.3%,差异有统计学意义(P<0.05)。Cripto-1高表达组病人的术后生存期短于Cripto-1低表达组的病人,差异有统计学意义(P<0.05)。COX多因素分析表明,Cripto-1表达阳性、临床JPS高分期和淋巴结转移是反映术后生存率的独立因素。结论:Cripto-1表达水平可能与胰腺导管腺癌的发生、发展、侵袭及转移相关,其确切的分子生物学机制有待进一步研究。

Objective To explore the expression of Cripto-1 in pancreatic ductal adenocareinoma and its clinical significance. Methods Cripto-1 expression was detected by immunohistochemistry in surgically resected specimens from 62 patients with pancreatic ductal adenocarcinoma. The associations were analyzed between Cripton-1 expression with clinical and pathologic characteristics. Results Cripto-1 expressed 67.7% in pancreatic ductal adenocarcinoma. The expression rate of Cripto-1 was 27.3% in well-differentiated tumors, 67.6% in moderately-differentiated tumors, and 94.1% in poorly-differentiated tumors （P〈0.05）. The expression rate of Cripto-1 was 58.7% in patients without vascular invasion and 93,8% in patients with vascular invasion （P〈0.05）. The expression rate of Cripto-I differed significantly between tumors with lymph node metastases（91.3%） and without（53.8%）（P〈0.05）. The survival was significantly shorter in patients with Cripto-1 positive expression compared to those with negative expression （P〈0.05）. COX multivariate analysis showed that positive expression of Cripto-1, high JPS clinical stage and lymph node metastases were the independent factors affecting survival rates. Conclusions The expression of Cripto-1 may be correlated with development, progression, invasion and metastasis of pancreatic ductal adenocarcinoma.